Polycystic Kidney, Autosomal Dominant: all 177 studies

Page 1 of 2. Open to participants first (39), then studies with results posted, then the rest; newest registration first within each.

• GBP-213 in Patients With Autosomal Dominant Polycystic Kidney DiseaseNot yet recruitingNCT07891364Early Phase 1
• Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral DoseNot yet recruitingNCT07868926Phase 1
• Effects of VX-407 on the Pharmacokinetics of Combined Oral ContraceptivesRecruitingNCT07792408Phase 1
• A Phase 1 Study of Single and Multiple Ascending Doses of GV-100RecruitingNCT07788014Phase 1
• Managing Depressive Symptoms in ADPKDRecruitingNCT07745920Not applicable
• Dietary Modulation of Urinary MCP-1 in ADPKDNot yet recruitingNCT07651397Not applicable
• Drug-Drug Interactions of JMKX003142 in Healthy ParticipantsNot yet recruitingNCT07565441Phase 1
• RADIOLOGICAL AND CLINICAL EVALUATION OF RENAL EMBOLIZATION USING EVOH IN DIALYSIS PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: A PROSPECTIVE LONGITUDINAL OBSERVATIONAL STUDYRecruitingNCT07535385
• A Study to Investigate the Effects of JMKX003142 on QTc Interval in Healthy AdultsNot yet recruitingNCT07470177Phase 1
• Mass Balance and Absolute Bioavailability Study of JMKX003142 In Healthy VolunteersNot yet recruitingNCT07463053Phase 1
• Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney DiseaseRecruitingNCT07454174Not applicable
• Bempedoic Acid Therapy for Polycystic Kidney DiseaseRecruitingNCT07282821Phase 2
• STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney DiseaseRecruitingNCT07280585Phase 3
• Hypertension in Children and Young People at Risk of Autosomal Dominant Polycystic Kidney DiseaseRecruitingNCT07260071
• Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney DiseaseRecruitingNCT07228364Phase 1
• Drug-Drug Interaction of JMKX003142 With Amiodarone and Febuxostat in Healthy SubjectsNot yet recruitingNCT07181265Phase 1
• Somatosensory Phenotyping of ADPKDRecruitingNCT06970028
• ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)RecruitingNCT06902558Phase 2
• Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)RecruitingNCT06800651Phase 2
• Di-PKD: A Pilot Trial of Dietary Intervention in Patients With Autosomal Dominant Polycystic Kidney DiseaseNot yet recruitingNCT06786260Not applicable
• Analysis of Patients With Autosomal Dominant Polycystic KidneyRecruitingNCT06759142
• Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003RecruitingNCT06714006Phase 1
• Study to Evaluate the Drug-drug Interaction of JMKX003142 in Healthy SubjectsNot yet recruitingNCT06658964Phase 1
• Shared Decision Making for Choosing Autosomal DOminant Polycystic Kidney Disease TreatmentRecruitingNCT06618638Not applicable
• Glucagon-Like Peptide-1 Receptor Agonist in ADPKDRecruitingNCT06582875Phase 2
• Treat Autosomal Dominant Polycystic Kidney Disease With Oral Ketone Ester?Not yet recruitingNCT06100133Phase 2
• National Registry of Rare Kidney DiseasesRecruitingNCT06065852
• Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare DiseasesRecruitingNCT05996731Not applicable
• Atorvastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney DiseaseEnrolling by invitationNCT05870007Phase 2
• A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver DiseaseRecruitingNCT05478083Phase 2
• HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of LifeRecruitingNCT05373264Phase 3
• Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)RecruitingNCT04939935Phase 3
• NOX4 and Related Biomarkers in ADPKDRecruitingNCT04630613
• Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)RecruitingNCT04344769
• Autosomal Dominant Polycystic Kidney Disease (ADPKD) StudyRecruitingNCT04338048
• A Prospective Observational Study of Foam Sclerotherapy .RecruitingNCT04111692
• Autosomal Dominant Polycystic Kidney Disease Somatic Mutation BiorepositoryEnrolling by invitationNCT03901521
• Early PKD Observational Cohort StudyRecruitingNCT02936791
• The German ADPKD Tolvaptan Treatment RegistryRecruitingNCT02497521
• Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT06435858Phase 2Results posted
• A Study of RGLS8429 in Healthy VolunteersCompletedNCT05429073Phase 1Results posted
• Effect of Beetroot Juice on Reducing Hypertension in Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT05401409Not applicableResults posted
• A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLDActive, not recruitingNCT05281328Phase 2/3Results posted
• Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303TerminatedNCT05208866Phase 3Results posted
• A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)TerminatedNCT04578548Phase 2Results posted
• Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney DiseaseTerminatedNCT04152837Phase 3Results posted
• Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney DiseaseTerminatedNCT04064346Phase 3Results posted
• A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCONTerminatedNCT03918447Phase 3Results posted
• An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)TerminatedNCT03749447Phase 3Results posted
• A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD PatientsTerminatedNCT03523728Phase 2/3Results posted
• The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT03487913Phase 2Results posted
• A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIXCompletedNCT03366337Phase 2Results posted
• Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT03342742Not applicableResults posted
• Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKDCompletedNCT03203642Phase 2Results posted
• Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)CompletedNCT02964273Phase 3Results posted
• Feasibility Study of Metformin Therapy in ADPKDCompletedNCT02903511Phase 2Results posted
• Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKDCompletedNCT02847624Results posted
• Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT02697617Phase 2Results posted
• Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT02656017Phase 2Results posted
• Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKDCompletedNCT02494141Phase 4Results posted
• Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT02251275Phase 3Results posted
• Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT02225860Phase 2/3Results posted
• Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT02160145Phase 3Results posted
• Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT01853553Phase 3Results posted
• Pasireotide LAR in Severe Polycystic Liver DiseaseCompletedNCT01670110Phase 2Results posted
• A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT01559363Phase 1/2Results posted
• 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT01451827Phase 2Results posted
• Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT01336972Phase 2Results posted
• A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]CompletedNCT01280721Phase 3Results posted
• Bosutinib For Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT01233869Phase 2Results posted
• Tolvaptan Extension Study in Participants With ADPKDCompletedNCT01214421Phase 3Results posted
• Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKDCompletedNCT01210560Phase 2Results posted
• A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]CompletedNCT01022424Phase 3Results posted
• Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to TherapyTerminatedNCT00920309Phase 2/3Results posted
• A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]CompletedNCT00841568Phase 2Results posted
• High Water Intake to Slow Progression of Polycystic Kidney DiseaseCompletedNCT00784030Not applicableResults posted
• Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT00456365Phase 3Results posted
• Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT00428948Phase 3Results posted
• Octreotide in Severe Polycystic Liver DiseaseCompletedNCT00426153Phase 2/3Results posted
• Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT00414440Phase 4Results posted
• Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT00413777Phase 2Results posted
• Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)CompletedNCT00286156Phase 1/2Results posted
• Robotic vs Open Nephrectomy for ADPKDActive, not recruitingNCT07355114
• Role of ROS and cAMP-PKA Biomarkers in ADPKDActive, not recruitingNCT07217158
• Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)Active, not recruitingNCT07161037Phase 2
• Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy ParticipantsCompletedNCT07074327Phase 1
• A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy ParticipantsCompletedNCT07022119Phase 1
• Simulated and Synthetic Health Data: Improving Clinical Research on Rare Diseases. A Real-World Data Simulation of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Trials. A Retrospective, Observational StudyActive, not recruitingNCT07016282
• Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney DiseaseActive, not recruitingNCT06747572
• A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney DiseaseActive, not recruitingNCT06734234Phase 1
• Artificial Intelligence-based Image Processing Methods to Advance the Characterization of Polycystic Kidney DiseaseActive, not recruitingNCT06688981
• A Possible Founding PKD2 Mutation Associated With Variable Phenotypes of ADPKD in Bergamo ProvinceCompletedNCT06594367
• Renal Oxygen Consumption, Insulin Sensitivity, and Daily Caloric Restriction in ADPKDActive, not recruitingNCT06496542Not applicable
• Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)Active, not recruitingNCT06391450Phase 4
• A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy ParticipantsCompletedNCT06345755Phase 1
• Study of Tamibarotene in Patients With ADPKDActive, not recruitingNCT06289998Phase 2
• Outcome of ADPKD With Octreotide LARActive, not recruitingNCT06193616
• Genetic Testing in Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT06085807
• Study and Management of Cystic Complications in Autosomal Dominant Polycystic Kidney DiseaseActive, not recruitingNCT06036992
• Thyroid Hormones in ADPKDCompletedNCT05646420Not applicable

← Polycystic Kidney, Autosomal Dominant overview